Anti-Amyloid Alzheimer’s Drugs Face New Doubts: Cochrane Review Finds ‘Trivial’ Effects
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.
Cochrane review anti-amyloid Alzheimer’s drugs Leqembi Kisunla trivial effects 2026
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals.
Cochrane Analysis: Little to No Clinical Benefit
The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.
Key findings at 18 months:
- Cognitive function: Probably little to no difference.
- Functional ability: Small effect at best.
- Dementia severity: May result in little to no difference.
“Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects,” the researchers concluded. They urge focusing on other mechanisms beyond amyloid plaques.
Drugs reviewed include failed candidates like Aduhelm, bapineuzumab, crenezumab, gantenerumab, and solanezumab plus approved Leqembi (Biogen/Eisai) and Kisunla (Eli Lilly).
Also Read : 10 Heart-Healthy Ingredient Substitutions to Lower Cholesterol and Protect Your Heart
Pharma Pushback on Leqembi, Kisunla Effectiveness
Eli Lilly slammed the review’s methodology: “It pools data from unsuccessful molecules with approved medicines, artificially diluting benefits.”
Both Leqembi and Kisunla earned full FDA approvals after showing statistically significant reductions in clinical decline in their Phase 3 trials. Still, Cochrane highlights decades of amyloid-targeting setbacks, including 2022 revelations of fabricated research fueling skepticism.
Safety Concerns: Brain Swelling Risks Rise
The drugs “probably result in a small increase” in ARIA-E (brain swelling visible on MRI). Results on ARIA-H (brain bleeding) were too inconsistent for pooling.
Top drugmakers like Biogen, Eisai, and Lilly have invested over a decade in these therapies, securing three FDA nods but this review reignites debates on Alzheimer’s treatment efficacy.
Related Stories
‘Universal’ Nasal-Spray Vaccine Shows Broad Protection in Mice Against Viruses, Bacteria and Allergens
A groundbreaking early-stage study suggests that a single nasal-spray vaccine could one day protect against multiple respiratory viruses, harmful bacteria, and even common allergens. In laboratory tests on mice, researchers found that an experimental vaccine triggered broad immune protection raising hopes for what scientists describe as a potential “universal” respiratory vaccine. However, experts caution that
10 Heart-Healthy Ingredient Substitutions to Lower Cholesterol and Protect Your Heart
10 Heart-Healthy Ingredient Substitutions for Better Cardiovascular Health Eating heart-healthy foods is one of the most effective ways to protect your cardiovascular system, lower disease risk, and support long-term wellness. The right nutrition can help regulate cholesterol, reduce high blood pressure, maintain healthy weight, and even aid recovery after a heart attack. Whether you’re preventing
Medicare Open Enrollment 2026: Major Changes, Costs, Drug Coverage Updates & Expert Advice
Medicare Open Enrollment 2026: Key Changes, Benefits, and What Seniors Must Know The Medicare Open Enrollment period for 2026 runs from October 15 to December 7, giving older adults the opportunity to join, switch, or update their Medicare plans. More than 69 million Americans depend on Medicare, and understanding the upcoming changes for 2026 is